Project Grant R41CA314866
Award Date 9/1/26
Completion Date 8/31/27
Dollars Obligated $400K
Federal Agency
Awardee
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Princeton, NJ, USA
Similar Awards
- This $399,499 Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), supports the development of Liquid Biotech's TELOMESCAN circulating tumor cell (CTC) assay for monitoring non-small cell lung cancer (NSCLC) patients undergoing radiation and immunotherapy. The key products and services to be delivered through this funding include: 1) Developing a clinical prototype of the TELOMESCAN assay with automated analysis to...
- The National Cancer Institute awarded Intus Biosciences LLC $404,338 on August 19, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop a non-invasive, bacterial biomarker-based screening assay for early-onset colorectal cancer in patients younger than 50 and precancerous lesions. The recipient will build the assay on Intus Biosciences' Titan-1 platform, a high-throughput strain-level bacterial profiling technology currently available as a laboratory developed...
- The National Cancer Institute awarded University of Connecticut Health Center $414,585 on May 6, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and validate a programmable enzyme-assisted mutation sequencing (PEAM-SEQ) diagnostic platform for detecting cell-free DNA mutations in blood samples to enable noninvasive, early detection of lung cancer. The project will advance a PCR-based PEAM-SEQ V1.0 assay into a simplified PEAM-SEQ V2.0 assay by combining...
- The National Science Foundation awarded Beken Bio, Inc. a $1,249,464 cooperative agreement on August 1, 2026, under the SBIR Phase II program to develop a liquid biopsy diagnostic tool that detects cancer through extracellular vesicle biomarkers in blood samples. The recipient will conduct a prospective, blinded clinical study of approximately 300 patients undergoing surgery to validate a diagnostic test that measures cancer signals carried by extracellular vesicles (EVs)—tiny particles released...
- The National Science Foundation awarded Rumedical Nova LIMITED Liability Company $305,000 on July 15, 2026, under the NSF Technology, Innovation, and Partnerships program (CFDA 47.084) to design and validate a compact chip-based platform for detecting lung cancer biomarkers in blood serum with high sensitivity and speed. The research will focus on developing an innovative nanoscale sensing element capable of recognizing disease signals at extremely low concentrations in a rapid, sensitive, and...
- The National Cancer Institute awarded Molecular Targeting Technologies, Inc. $637,529 on August 24, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop targeted radionuclide therapy for non-small cell lung cancer using Lu-177 EBRGD. The award funds research to evaluate in vivo tumor targeting, biodistribution, therapeutic efficacy, and normal tissue toxicity of 177Lu-DOTA-EB-RGD as a treatment for non-small cell lung cancer, which accounts for 80–85 percent...
- The National Cancer Institute awarded Sesh Incorporated a Cooperative Agreement worth $406,500 on September 12, 2025, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop and commercialize a blood-based liquid biopsy assay for detecting HLA LOH (human leukocyte antigen class I loss of heterozygosity) in cancer patients with solid tumors. Sesh's RELOAD assay uses cell-free DNA next-generation sequencing to identify HLA LOH without requiring surgical tumor biopsy,...
- The National Institutes of Health National Cancer Institute awarded The Leland Stanford Junior University $638,972 on August 1, 2026, under the Cancer Detection and Diagnosis Research program (CFDA 93.394) to develop an integrated liquid biopsy framework for noninvasive characterization of peripheral T-cell lymphomas. The funded research integrates circulating cell-free DNA and cell-free RNA analysis to detect minimal residual disease, monitor disease dynamics, improve disease classification,...
- Federal Grant Award Summary Cereus Diagnostics Corp. received a $764,448 Project Grant from the National Cancer Institute under the Cancer Detection and Diagnosis Research Program (CFDA 93.394) awarded on August 1, 2025, with completion targeted for July 31, 2028. The company is developing LUNG-FAST (Fragment Analysis, SNP, and Translocations), a rapid polymerase chain reaction (PCR)-based diagnostic test designed to detect clinically actionable lung cancer mutations including EGFR, KRAS, ALK,...
- The National Cancer Institute awarded Daybreak Pharmaceuticals Inc. $303,345 on September 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to develop a first-in-class synthetic RNA-based therapy targeting the mutagenic translesion synthesis pathway to enhance chemotherapy efficacy in non-small cell lung cancer. The project delivers proof-of-concept evaluation of translesion synthesis inhibition using a nucleic acid construct encoding a dominant-negative REV1 C-terminal...